CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2013-04-11): ART for HIV may protect against HBV

Clinical

ART for HIV may protect against HBV

Last Updated: 2013-04-11 14:45:09 -0400 (Reuters Health)

NEW YORK (Reuters Health) - In a study of men with HIV, antiretroviral therapy (ART) with lamivudine or tenofovir disoproxil fumarate (TDF) appeared to protect against infection with hepatitis B virus (HBV), Japanese researchers say.

Dr. Hiroyuki Gatanaga of the National Center for Global Health and Medicine, Tokyo and colleagues evaluated stocked serum samples from HIV-infected men who have sex with men.

They found a lower frequency of incident HBV infection under lamivudine- and TDF-containing ART than under ART without lamivudine and TDF, or without ART at all, Dr. Gatanaga told Reuters Health by email, adding that "HBV-active ART seems to work as a pre-exposure prophylaxis against HBV."

As reported March 13th online in Clinical Infectious Diseases, the research team had access to "first stocked blood samples" from 1,434 HIV-infected men who hadn't been vaccinated against HBV; 354 were negative for all analyzed HBV serological markers.

During follow-up of the latter group, analysis of their last samples indicated HBV incident infection in 43 (12.1%).

Rates of incident infections per 100 person-years were 0.669 during lamivudine- or TDF-containing ART, 6.726 with no ART, and 5.263 with some other type of ART.

However, it seems that lamivudine-resistant strains may evade the drug's protective effect. These infections were more prevalent during ART with lamivudine (50%) than during no or other ART (7.1%).

In fact, Dr. Gatanaga added, "In order to prevent lamivudine-resistant HBV infection, TDF-ART should be used instead of (lamivudine)-ART."

Also, Dr. Gatanaga pointed out, "Some doctors are trying to use a NRTI-sparing regimen because they want to avoid NRTI toxicity such as mitochondrial damage. But NRTI-sparing regimens do not have HBV-prophylactic effects."

Dr. Gatanaga believes the same prophylactic effects should also work in women.

SOURCE: http://bit.ly/156fkzy

Clin Infect Dis 2013.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.